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Table 1
Top 25 Questions in the Research Agenda for VAP
1) What is the role of clinical microbiologists in VAP diagnosis?
2) What is the best diagnostic paradigm for VAP?
3) What time is acceptable for rapid diagnostic tests?
4) What is the duration of prior antibiotic exposure inﬂuencing identiﬁcation
and outcome?
5) How to differentiate between infection vs. colonization of lower respiratory
tract?, 6) Is it relevant to differentiate VAP from ventilator-associated
tracheobronchitis (VAT)?
7) What is the role of respiratory viruses in VAP?
8) Are chest-X rays needed or can be replaced by lung ultrasounds?
9) What is the role of biomarkers and ‘omics’, if any, in diagnosis?
10) Patients with tracheostomy and endotracheal tubes are comparable?
11) Adults data can be transferred to mechanically ventilated children?
12) What is the role of hypoxemia in the decision-process making?
13) How to stratify (for severity and benchmarking) different VARI and its
inﬂuence in diagnosis?
14) How to optimize diagnosis to increase patient enrollment in randomized
clinical trials?
15) What is the cost-efﬁcacy of new diagnostic tests?
16) When is the VAP onset?
17) Does techniques used in reference centers can be applied in
non-university hospitals.
18) What diagnosis strategy should be implemented in low-income and
middle-income countries?
19) What is the contribution of identifying virulence factors in diagnosis
of VAP?
20) Are new diagnostic tools improving outcomes and justifying
increasing costs?
21) How predetermined colonization pressure inﬂuences diagnosis?
22) Is feasible to identify pneumonia onset with anticipation for pre-emptive
therapy?
23) What is the contribution of surveillance to diagnosis?
24) Is diagnosis using a signature in breath expired metabolites a
non-invasive technique contributing to better identiﬁcation?
25) What are the responsible agents for episodes with unidentiﬁed organisms
and how to reduce its prevalence?Ventilator-associated pneumonia (VAP) diagnosis is a challenge
because gold standard is lacking and conﬁrmation is based on
respiratory cultures and techniques with important limitations.
Presentation with clinical signs of community-acquired pneumo-
nia is unusual, bacteremia is uncommon, onset undetermined, and
it usually presents as progressive hypoxemia (or increase in
vasoactive drugs) in a ventilated patient with purulent respiratory
secretions, being a post-hoc diagnosis after ruling out other
infectious sites 1. Half episodes are caused by unidentiﬁed
organisms and heterogeneity in diagnosis is huge, with important
geographical differences in strategies and pathogens 2,3. Moreover,
microbiologic tests may require hours to days of incubation and,
classically, additional time is needed to identify organisms and
further determination of susceptibility. For that reason, in general,
antimicrobial therapy is empirical and often requires broad
spectrum with subsequent emergence of antimicrobial resistance.
Also, and more importantly, it is essential to develop fast
diagnostic techniques and investigate airways microbe population
that can immediately predict causative microorganisms without
specimen processing. In this context, still remain many important
research questions which need to be answered (Table 1).
In this issue of the International Journal of Infectious Diseases,
Prat and Lacoma (ref) describe the clinical role of bacteria in the
respiratory tract and review novel therapeutic approaches. Its
excellent review is welcome because contains interesting consid-
erations that can help to answer some of the formulated questions.
We agree with the authors that the role of clinical microbiol-
ogists is not limited to report a laboratory result; their expertise in
laboratory diagnostic methods, susceptibility testing and interpre-
tation of microbiological results go beyond that and should be taken
for the optimal management of patients. In our opinion, a team
working with ﬂuent communication is highly recommended for
optimal management; indeed, all microbiological results should be
interpreted based on patient comorbidities, period of hospitaliza-
tion, previous antibiotics and clinical presentation (hypoxemia) and
images 4. To detect bacteria in a respiratory sample does not mean
an infection. Even if presumed, we have to translate it to the contexthttp://dx.doi.org/10.1016/j.ijid.2016.09.019
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).patient before taking therapeutic decisions. We disregard decisions
based only on microbiologic ﬁndings.
In this scenario, what is the optimal diagnostic approach for
VAP? The recent Guidelines published by the Infectious Diseases
Society of America/The American Thoracic Society (IDSA/ATS)
provide recommendations for diagnosis and treatment of adults
with Hospital-acquired (HAP) and VAP 5. These guidelines suggest
performing, with low quality evidence, noninvasive samples
(endotracheal aspiration) with semiquantitive cultures for VAP
diagnosis. Once again, a personalized approach is required; we
agree with the recommendation in the use of noninvasive samples
because there is low evidence of superiority on outcomes of
invasive samples in non-immunocompromised patients; however,
based in our experience, quantitative methods (that report numberociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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because they are associated with high speciﬁcity and informs on
bacteria burden which correlates with probability of infection
4. However, immunocompromissed patients require brochoalveo-
lar lavage and lung transplants 6 might beneﬁt of a transbronchial
biopsy. We also endorse the use of E-test antibiotic strips applied
directly to respiratory tract samples. Bouza et al., 7 reported that
use of rapid E-test was associated with increased administration of
appropriate antimicrobial therapy and reduced the report of
antimicrobial susceptibility in 1.4 days (compared with 4.2 days
for those using standard diagnostic methods). Then, the difﬁculty
in the differentiation between infection vs. colonization remains a
challenge nowadays. This represents, in our opinion, a key point in
the research agenda in VAP. The introduction of polymerase chain
reaction (PCR) tests has increased the ability to detect micro-
organisms in clinical samples, including those difﬁcult to grow.
Adding mecA identiﬁcation to specimens with Gram-positive cocci
(or GenExpert1 to Gram-negative specimens) is already an
advance 8 in this way. However, differentiation between coloniza-
tion, active infection or excretion of non-viable microorganisms
remains an open issue with newer molecular techniques. Novel
technologies such as gene expression diagnostics 9 and also the
study of respiratory microbiome are very promising tools that
could allow us to enter into the era of ‘‘personalized medicine’’.
Quantitative techniques might split colonization from infection.
We strongly believe that only point-of-care tests, available within
two hours, justify increasing costs, being able to modify outcomes.
Introducing molecular tests require a new paradigm focusing on
phenotypes rather than the organism, and trials are needed to
measure the impact on appropriate antibiotic use, stewardship,
time to resolution and period of MV as primary end-points.
Microarrays are the most frequently used gene expression
platform, being a promising tool for improving diagnosis in Lower
Respiratory Tract Infection (LRTI), demonstrating its usefulness in
the differentiation of bacterial and viral infections 10,11. This
technique is based on the immune response of the patient against
the pathogen rather than detection of the microorganisms. The
human microbiome is also a new non-culture-based technique
that has been developed to characterize the entire population of
microbes resident on the body surfaces. Recent studies have shown
that investigation of the respiratory microbiome is an emerging
ﬁeld, and these ﬁndings may provide a different vision about
respiratory diseases 12,13, suggesting that airways have a micro-
biome that varies from health to disease 14. Understanding the
factors that affect the composition of the lower airway microbiota
in VAP will help us to look for new therapeutics and diagnosis
challenges to improve outcome in this patients.
Another factor that should be considered in the research agenda
in VAP is the differentiation between bacteria and respiratory
viruses. What is the role of respiratory viruses in the development
of VAP? This question has not yet been answered. After the
2009 inﬂuenza A (H1N1) pandemic it was established the
importance of this virus causing pneumonia 15. However, the role
of respiratory virus in the development of VAP is still under-
estimated and only few studies analyze severe pneumonia and
viral etiology. In the study performed in Finland by Karhu et al., 16,
it was found a viral etiology of severe pneumonia in 24 patients
(49%). Although, a viral etiology is currently recognized as a cause
of severe pneumonia, no recommendation was done in the
2016 IDSA/ATS Guidelines 5. In our opinion, we also need more
studies to understand the role of cytomegalovirus and herpes virus
17,18 in ventilated patients.
Biomarkers are another piece of the VAP diagnosis that need
more research effort. The 2016 IDSA/ATS guidelines recommended
avoid performing biomarkers for diagnosis. Sequential use of old
and newer biomarkers is more promising 19, particularly toanticipate poor resolution, and more studies are needed, enclosing
metabolomics in breath condensate of the espiratory tube.
Current interest emerges in identifying ventilator-associated
tracheobronchitis (VAT) and differentiating from VAP, because it is
increasing MV period 6. Indeed, it is treated with aerosolized
antibiotics in many ICUs 20. Chest radiographs are expensive, time-
consuming and difﬁcult to assess, and bedside ultrasounds 21 can
replace it in trained sites, because they have additional beneﬁts
when performed bedside. We believe that the concept of
ventilator-associated respiratory infections (VARI) has advantages
and in the decision process it might be more important the degree
of hypoxemia rather than chest images 1. Finally, as documented
by Pen˜a-Lopez et al in children 22, where limited literature is
available, differences between artiﬁcial airways (tracheostomy or
endotracheal tube) should not be missed in VARI.
In conclusion, the research agenda should focus on a new
paradigm focusing on antibiotic susceptibility rather than organ-
isms. Speed is life, so in addition to Gram stain, what molecular
tests (and biomarkers) can contribute to improve diagnosis with
management implications within the ﬁrst two hours after
diagnosis need to be identiﬁed. This is not only of academic
interest, due the current scenario of limited antimicrobial options
and the urgent need to improve enrolment23 in HAP/VAP clinical
trials.
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